More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$688171418
EPS
-3.3
P/E ratio
--
Price to sales
12.21
Dividend yield
--
Beta
0.554655
Previous close
$7.09
Today's open
$7.68
Day's range
$7.23 - $7.75
52 week range
$6.75 - $13.90
show more
CEO
Troy E. Wilson
Employees
260
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
91878694
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Kura Oncology, Inc. (KURA) Presents at UBS Global Biopharma Conference 2026 Transcript
Kura Oncology, Inc. ( KURA ) UBS Global Biopharma Conference 2026 November 17, 2026 8:20 AM EST Company Participants Jennifer Fulk - Chief Financial Officer Brian Powl - Chief Commercial Officer Mollie Leoni - Chief Medical Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right. Great. Well, thank you, everyone, for joining us.
Seeking Alpha • a day ago

Kura Oncology: Refills Drive Komzifti Launch, While Funding Bridge Sets The Pace
Kura Oncology is a BUY: KOMZIFTI uptake and a roughly $202 million enterprise value support a measured event-driven position. KOMZIFTI prescriptions outpaced new starts, suggesting growing refills; patient-level persistence and treatment duration remain unproven. KURA's funding bridge beyond the first 2028 topline is plausible, not assured, and depends on milestones, eligible debt draws, product receipts, and spending discipline.
Seeking Alpha • Nov 17, 2026

Kura Oncology to Participate in Two Investor Conferences in November
SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:
GlobeNewsWire • Nov 13, 2026

Kura Oncology, Inc. (KURA) Q3 2026 Earnings Call Transcript
Kura Oncology, Inc. ( KURA ) Q3 2026 Earnings Call November 10, 2026 4:30 PM EST Company Participants Greg Mann - Senior Vice President of Investor Relations & Corporate Affairs Troy Wilson - Chairman, CEO & President Brian Powl - Chief Commercial Officer Mollie Leoni - Chief Medical Officer Jennifer Fulk - Chief Financial Officer Conference Call Participants Nabeel Nissar - Jefferies LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Jason Zemansky - BofA Securities, Research Division Priyanka Grover - JPMorgan Chase & Co, Research Division Salim Syed - Mizuho Securities USA LLC, Research Division Peter Green - LifeSci Capital, LLC, Research Division Philip Nadeau - TD Cowen, Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Operator Good day, everyone. My name is Ronnie, and I will be your conference operator today.
Seeking Alpha • Nov 11, 2026

Kura Oncology Q3 Earnings Call Highlights
Kura Oncology NASDAQ: KURA reported third-quarter 2026 net product revenue of $13.9 million for leukemia treatment KOMZIFTI, up 53% from the prior quarter, as the company expanded prescribing accounts and prepared clinical data on combinations with other therapies.
MarketBeat • Nov 11, 2026

Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
– KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority share of new patient starts of the menin inhibitor class in the R/R NPM1-mutated AML market – – Eight abstracts accepted for ASH 2026, including two oral presentations on FLT3 inhibitor combinations, highlighting expanding development of ziftomenib in AML – – FDA alignment for approximately 40-patient monotherapy registrational study of darlifarnib in HRAS-mutated salivary gland cancer; study initiation targeted for 1H 2027 – – Darlifarnib combination studies in renal cell and pancreatic cancers expected to reach key development milestones in 2027 – – Strong financial position, supported by $492.1 million in cash, cash equivalents and short-term investments, anticipated Kyowa Kirin collaboration payments and up to $300 million additional financing capacity from Oberland Capital – – Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m.
GlobeNewsWire • Nov 10, 2026

Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates
Kura Oncology (KURA) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.85 per share a year ago.
Zacks Investment Research • Nov 10, 2026

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on November 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 55,500 shares of common stock to three (3) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewsWire • Nov 6, 2026

Kura Oncology (KURA) Loses 35.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Kura Oncology (KURA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks Investment Research • Nov 6, 2026

Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –
GlobeNewsWire • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Kura Oncology Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.